Compare Rocket Companies Inc. Class A Common Stock (RKT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Companies Inc. Class A Common Stock vs BIO-TECHNE Corp — how do they compare? Rocket Companies Inc. Class A Common Stock trades at $10.79 (market cap $29.82B), while BIO-TECHNE Corp trades at $72.68 (market cap $11.37B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 2.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Rocket Companies Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Companies Inc. Class A Common Stock for 0 Days and BIO-TECHNE Corp for 64 Days on average.
| RKT | TECH | |
|---|---|---|
Market Cap | $29.82B | $11.37B |
Volume | 46,995,062 | 1,544,768 |
Sector | Financials | Health |
52-Week High | $23.44 | $72.61 |
52-Week Low | $10.53 | $43.31 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $59.81B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Bio-Techne (TECH) trades at $72.48, down 0.11% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average support. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. The company's pending acquisition by Merck KGaA for $73.00 per share, approved by shareholders (PRNewsWire, 2026-09-23), is a key near-term catalyst. Fundamentals indicate solid profitability with a 65.77% gross margin but elevated valuation ratios like a P/E of 62.52.
The outlook is dominated by the acquisition, offering a clear exit near the current price. Upside is capped by the deal price, while execution risks or regulatory hurdles pose downside. Analyst sentiment is neutral with a consensus hold rating. The stock presents a low-risk opportunity for merger arbitrage but limited growth potential for long-term investors absent competitive threats or integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
